VIVOS THERAPEUTICS INC (VVOS)
US92859E2072 - Common Stock
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | 2025 | ||
|---|---|---|---|---|---|---|
| Revenue YoY % growth | 16.89M 29.23% | 16.02M -5.15% | 13.801M -13.85% | 15.506M 12.35% | 19.54M 26.02% | |
| EBITDA YoY % growth | -18.74M -65.55% | -24.36M -29.99% | -16.675M 31.55% | -12.648M 24.15% | -9.18M 27.42% | |
| EBIT YoY % growth | -19.47M -61.71% | -25.03M -28.56% | -17.296M 30.90% | -11.16M 35.48% | -7.029M 37.02% | |
| Operating Margin | -115.28% | -156.24% | -125.32% | -71.97% | -35.97% | |
| EPS YoY % growth | -9.14 40.26% | -20.08 -119.69% | -10.92 45.62% | -2.30 78.98% | -1.09 52.67% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.40 86.79% | -0.79 51.82% | -0.63 -5.40% | -0.35 13.30% | -0.52 -29.11% |
| Revenue Q2Q % growth | 4.751M 46.27% | 4.08M 19.33% | 4.284M 5.67% | 4.59M 18.91% | 4.896M 3.05% |
| EBITDA Q2Q % growth | -2.652M 27.60% | -2.55M 29.93% | -2.346M -42.61% | -2.244M -1.63% | -1.938M 26.92% |
| EBIT Q2Q % growth | -2.627M 38.69% | -2.55M 32.63% | -2.346M -21.18% | -2.244M 15.16% | -1.938M 26.21% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.40 75.31% | -0.62 | 0.22 | 35.71% |
| Q2 2024 Q2Q % growth | -0.60 86.67% | -1.07 | 0.47 | 43.98% |
| Q1 2024 Q2Q % growth | -1.63 6.86% | -1.20 | -0.43 | -36.00% |
| Q4 2023 Q2Q % growth | -3.05 39.00% | -1.94 | -1.11 | -56.97% |
| Q3 2023 Q2Q % growth | -1.62 -390.91% | -3.19 | 1.57 | 49.18% |
| Q2 2023 Q2Q % growth | -4.50 45.45% | -3.70 | -0.80 | -21.70% |
| Q1 2023 Q2Q % growth | -1.75 73.08% | -4.59 | 2.84 | 61.87% |
| Q4 2022 Q2Q % growth | -5.00 41.18% | -5.61 | 0.61 | 10.87% |
| Q3 2022 Q2Q % growth | -0.33 -26.92% | -0.27 | -0.06 | -22.09% |
| Q2 2022 Q2Q % growth | -8.25 -4,242.11% | -7.14 | -1.11 | -15.55% |
| Q1 2022 Q2Q % growth | -6.50 -3,321.05% | -6.63 | 0.13 | 1.96% |
| Q4 2021 Q2Q % growth | -8.50 -865.91% | -6.38 | -2.13 | -33.33% |
| Q3 2021 Q2Q % growth | -0.26 | -0.19 | -0.07 | -37.78% |
| Q2 2021 Q2Q % growth | -0.19 | -0.18 | -0.01 | -3.49% |
| Q1 2021 Q2Q % growth | -0.19 | -0.17 | -0.02 | -9.57% |
| Q4 2020 Q2Q % growth | -0.88 | -0.17 | -0.71 | -422.88% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | 3.86M 16.93% | 4.142M | -282K | -6.81% |
| Q2 2024 Q2Q % growth | 4.054M 19.41% | 3.672M | 382K | 10.40% |
| Q1 2024 Q2Q % growth | 3.419M -11.36% | 3.479M | -60K | -1.72% |
| Q4 2023 Q2Q % growth | 3.248M -17.77% | 3.474M | -226K | -6.51% |
| Q3 2023 Q2Q % growth | 3.301M -22.33% | 4.223M | -922K | -21.83% |
| Q2 2023 Q2Q % growth | 3.395M -18.78% | 4.229M | -834K | -19.72% |
| Q1 2023 Q2Q % growth | 3.857M 5.96% | 4.086M | -229K | -5.60% |
| Q4 2022 Q2Q % growth | 3.95M -10.02% | 4.642M | -692K | -14.91% |
| Q3 2022 Q2Q % growth | 4.25M -6.59% | % | ||
| Q2 2022 Q2Q % growth | 4.18M -7.11% | 3.885M | 295K | 7.59% |
| Q1 2022 Q2Q % growth | 3.64M 5.51% | 4.531M | -891K | -19.66% |
| Q4 2021 Q2Q % growth | 4.39M 32.63% | 4.951M | -561K | -11.33% |
| Q3 2021 Q2Q % growth | 4.55M 38.30% | 4.592M | -42K | -0.91% |
| Q2 2021 Q2Q % growth | 4.5M -30.42% | 3.671M | 829K | 22.58% |
| Q1 2021 Q2Q % growth | 3.45M | 3.317M | 133K | 4.01% |
| Q4 2020 Q2Q % growth | 3.31M 8.17% | 3.273M | 37K | 1.13% |
| Q3 2020 Q2Q % growth | 3.29M -0.90% | % |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 40.6% | 0% | 32.74% |
| Revenue | 0% | 4.03% | -10.11% | -4.43% |